首页|PET/CT诊断药物68Ga-FAPI-04的应用进展

PET/CT诊断药物68Ga-FAPI-04的应用进展

扫码查看
成纤维细胞活化蛋白(FAP)是一种Ⅱ型膜结合糖蛋白,其在90%的上皮肿瘤、伤口愈合或炎症部位的成纤维细胞中过表达,而在正常组织中低表达或不表达,是疾病诊疗的重要靶点之一.68Ga-FAPI-04是基于喹啉类FAP抑制剂开发的PET诊断药物,在患者体内外均表现出对FAP的高度特异性与亲和力,在基础研究及临床应用中均得到广泛关注.笔者就68Ga-FAPI-04的基本概况及其在多种恶性肿瘤、非肿瘤疾病中的应用进展进行综述.
Progress in the application of PET/CT diagnostic drug 68Ga-FAPI-04
Fibroblast activation protein(FAP)is a type Ⅱ membrane-bound glycoprotein that is overexpressed in fibroblasts of 90%epithelial tumors,wound healing or inflammatory sites,but is low or absent in normal tissues,and is an important target for disease diagnosis and treatment.68Ga-FAPI-04 is a PET diagnostic drug based on quinoline-based FAP inhibitors,which has shown high specificity and affinity for FAP in patients both in vivo and in vitro,and has received wide attention in basic research and clinical applications.The author reviewed the basic overview of 68Ga-FAPI-04 and its application in various malignant and non-cancerous diseases.

Positron-emission tomographyTomography,X-ray computedFibroblast activation proteinNeoplasns68Ga-FAPI-04

李攀峰、于江、侯文彬、李祎亮

展开 >

天津中医药大学研究生院,天津 301617

中国医学科学院北京协和医学院放射医学研究所,天津市放射医学与分子核医学重点实验室,先进医用材料与医疗器械全国重点实验室,天津市医学健康研究院,天津 300192

正电子发射断层显像术 体层摄影术,X线计算机 成纤维细胞活化蛋白 肿瘤 68Ga-FAPI-04

2024

国际放射医学核医学杂志
中华医学会 中国医学科学院放射医学研究所

国际放射医学核医学杂志

CSTPCD
影响因子:0.227
ISSN:1673-4114
年,卷(期):2024.48(7)